公司已于2026年1月完成乐康制药100%股权转让(价格6250万元)，并于2025年12月完成罗欣安若维他 20%股权转让。这些处置有助于减少非经营性损益拖累，后续亏损影响将逐步消除。 经济观察网罗欣药业（002793）近期发布2025年业绩预告，预计归母净利润亏损显著收窄，同时核心创 新药替戈拉生片商业化放量，研发管线取得关键进展。 业绩经营情况 公司于2026年1月30日发布业绩预告，预计2025年归母净利润亏损收窄至-2.5亿元至-3.4亿元，较2024年 同期亏损(-9.65亿元)显著改善。扣非净利润预计为-2.6亿元至-3.5亿元。后续需关注审计机构的最终审计 结果，正式年报预计在2026年4月前披露。 业务进展情况 国家1类创新药替戈拉生片(泰欣赞)的三大适应症已全面纳入2025年版国家医保目录，支付端障碍消 除。2025年上半年，该产品进院数量激增近2500家，销售量同比增长约140%。未来其销售规模效应和 运营效率的提升值得跟踪。 产品研发进展 公司重点研发的注射用LX22001目前已进入Ⅱ期临床试验阶段；普卡那肽片Ⅲ期临床研究报告已完成定 稿，正推进地产化落地。这些创新药进展可能影响公司长 ...

Core Viewpoint - Recent asset transactions by Luoxin Pharmaceutical highlight the company's ongoing financial struggles, with significant losses and high debt levels prompting asset sales at steep discounts [1][2][6] Financial Performance - As of September 30, 2025, Luoxin Pharmaceutical's total assets were 12.00 billion, with total liabilities at 4.68 billion, resulting in a debt ratio of 61.65% [2][8] - The company reported a net loss of 1.44 billion for the first three quarters of 2025, following a loss of 14.48 billion in 2022 and 6.39 billion in 2023, totaling over 28 billion in losses over three years [10][11] - The company's cash reserves have drastically decreased from 20.02 billion at the end of 2021 to 3.93 billion by mid-2025, a decline of over 80% [11] Asset Sales - Luoxin Pharmaceutical sold its subsidiary, Lekang Pharmaceutical, for 62.5 million, significantly below its net asset value of 73.24 million and only 15% of its registered capital of 420 million [1][6] - The initial listing price for Lekang was 190 million, but after multiple price reductions, it was sold at a 67% discount [8] Business Challenges - The company's core generic drug business has been severely impacted by policy changes, with revenue from generics accounting for approximately 98% of total income, while the average gross margin in the industry has dropped from 75% in 2020 to about 60% [11] - Luoxin's revenue has plummeted from a peak of 6.48 billion in 2021 to 2.65 billion in 2024, indicating a significant contraction in business scale [10] Innovation and R&D - Despite the financial difficulties, Luoxin's innovative drug, Tegoprazan, has shown promising sales, exceeding 2.7 billion in the first half of 2025, marking a nearly 140% increase [12] - However, the company has reduced its R&D spending from 2.05 billion in 2022 to 0.63 billion in the first three quarters of 2025, indicating a shift towards marketing over research [12][13] - Luoxin plans to raise up to 842.4 million through a private placement to support R&D and working capital, but this funding will take time to materialize [12]

Core Viewpoint - The recent personnel changes at Luoxin Pharmaceutical, particularly the replacement of Liu Zhenteng with Chen Yu as the legal representative and general manager of Shandong Luoxin, signify a strategic shift aimed at clarifying internal roles and enhancing operational efficiency [1][3][4]. Group 1: Personnel Changes - Liu Zhenteng, the son of the founder, has stepped down from his roles at Shandong Luoxin but remains as chairman of Luoxin Pharmaceutical [1][3]. - Chen Yu, a veteran with extensive technical and production experience, has taken over as general manager, which is expected to improve the company's production and operational quality [3][4]. - The company has undergone at least eight personnel changes in 2025, indicating a trend towards appointing executives with financial and auditing backgrounds to strengthen capital operations and financial structure [5][6][19]. Group 2: Financial Performance - Shandong Luoxin's revenue has significantly declined from 64.81 billion to 22.92 billion from 2021 to 2024, with net profits showing losses of -10.34 billion, -5.37 billion, and -6.32 billion during the same period [4][16]. - In the first half of 2025, Shandong Luoxin managed to turn a profit of 21.93 million, indicating a potential recovery [4][16]. - Luoxin Pharmaceutical has also faced declining revenues and profits, with net losses of -14.48 billion, -6.39 billion, and -7.68 billion from 2022 to 2024, raising concerns about the risk of being classified as a "ST" (special treatment) company [7][19]. Group 3: Strategic Initiatives - The company is actively pursuing asset optimization strategies, including the sale of subsidiaries to improve resource allocation and liquidity [9][21]. - Luoxin Pharmaceutical plans to raise up to 842.4 million through a targeted A-share issuance to fund innovative drug development and facility upgrades [10][22]. - The company has received a significant capital injection of 130 million from a local government fund, which is expected to provide essential support for its operations and strategic initiatives [10][22].

Core Viewpoint - 罗欣药业 is strategically focusing on the pharmaceutical industry, with significant growth in its core innovative drug, 泰欣赞, and plans for further development in the digestive system field. Group 1: Company Performance - As of December 31, 2025, 罗欣药业's stock closed at 4.8 yuan, down 1.44% from the previous week, with a total market capitalization of 5.22 billion yuan, ranking 97th in the chemical pharmaceutical sector [1] - 泰欣赞's sales volume increased by nearly 140% year-on-year, with the number of hospitals using the drug approaching 2,500 [1][4] - The gross profit margin for the first three quarters reached 51.8%, and operating cash flow turned positive at 280 million yuan [4] Group 2: Product Development - 泰欣赞 has achieved full coverage in the medical insurance directory for its three indications: gastroesophageal reflux disease, duodenal ulcers, and eradication of Helicobacter pylori [1][4] - The drug's advantages over PPI include rapid onset, prolonged acid suppression, and effective control of nighttime acid breakthrough [1] - The company is advancing its research pipeline, with the injection drug LX22001 entering phase II clinical trials and the report for the phase III clinical study of 普卡那肽片 completed [1] Group 3: Strategic Initiatives - 罗欣药业 plans to raise up to 842.4 million yuan through a refinancing project aimed at funding innovative drug research, raw material drug expansion, and supplementing working capital [2][4] - The company is optimizing processes for potential centralized procurement products and building a product matrix that supports innovative drugs and differentiated generics [2] Group 4: Corporate Transactions - 罗欣药业's subsidiary, 山东罗欣, intends to transfer its 100% stake in 山东罗欣乐康制药有限公司 for a consideration of 62.5 million yuan, which will no longer be included in the consolidated financial statements post-transaction [2][4]

Core Viewpoint - 罗欣药业 plans to raise up to 842 million yuan through a private placement of shares to fund innovative drug research, raw material drug expansion, and working capital supplementation, without changing its control [1] Fundraising and Project Allocation - The company intends to issue no more than 326,276,545 A-shares, raising a total of up to 842 million yuan for various projects [1] - Among the fundraising projects, 226 million yuan is allocated for innovative drug research, with 207 million yuan sourced from the raised funds [2] - The innovative drug research includes clinical studies for LX22001 and Tegoprazan, aimed at expanding treatment indications and enhancing market competitiveness [2] Raw Material Drug Expansion and Technological Upgrades - The raw material drug expansion and freeze-drying workshop technological upgrade project has a total investment of 476 million yuan, with 383 million yuan planned to be funded from the raised capital [3] - This project aims to upgrade production standards and respond to regulatory trends, while also supporting the company's international development strategy [3] Financial Performance and Historical Context - Since its A-share listing in 2020, the company has faced significant financial instability, with cumulative losses exceeding 2.8 billion yuan over the past three years [4] - Revenue figures from 2020 to 2024 show a decline from 60.96 billion yuan to 26.47 billion yuan, with a notable drop of 44.62% in 2022 [5] - The company reported a net profit of 3.21 billion yuan in 2020, which fell to a loss of 12.25 billion yuan in 2022, reflecting a 401.63% decline [5] Market Position and Product Development - The company has been actively developing innovative drugs, with Tegoprazan being a significant contributor to revenue growth, particularly in the digestive system category [6] - Sales of Tegoprazan increased by 163.63% and 43.11% in 2023 and 2024, respectively, with a nearly 140% increase in the first half of 2025 compared to the previous year [6] Research and Development Expenditure - R&D expenses have been declining from 361 million yuan in 2020 to 87 million yuan in 2024, while sales expenses have remained significantly higher [7] - The company reported a revenue of 1.077 billion yuan in the first half of 2025, a 14.45% decrease year-on-year, but a net profit of 17.69 million yuan, marking a 119.95% increase [7] Management Changes - The company has experienced frequent changes in its management team, with several key resignations occurring in 2024 and 2025 [7]

Group 1: Financial Performance - The company experienced a significant revenue decline in Q1 2025 due to reduced demand for respiratory and antibiotic products caused by a warm winter [2][3] - In Q4 2024, the company reported substantial losses primarily due to asset impairment provisions and fair value changes of financial instruments, which are non-operational impacts [3][5] - The company achieved profitability in Q1 2025, driven by increased sales of the innovative drug, Tegoprazan, and effective collection of receivables, improving cash flow and reducing bad debt losses [3][4] Group 2: Product Development and Pipeline - The innovative drug LX22001 is currently in Phase II clinical trials, while the clinical research report for Pucanatide tablets has been finalized and is moving towards commercialization [2][3] - The company has over 10 generic drugs in development or submitted for approval, which are expected to contribute to future revenue growth [3][4] Group 3: Market Strategy and Growth Plans - The company plans to significantly increase hospital access for its innovative drugs, with a target of a 130% increase in hospital entries by the end of 2024 [3][4] - The company is focusing on optimizing its supply chain and reducing fixed costs through various measures, including organizational restructuring and talent assessment [4][5] Group 4: Shareholder Information - As of May 9, 2025, the total number of shareholders is 31,442 [5]